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Abstract
IMPORTANCE—Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause 
of genetic Parkinson disease (PD) known to date. The clinical features of manifesting LRRK2 
mutation carriers are generally indistinguishable from those of patients with sporadic PD. 
However, some PD cases associated with LRRK2 mutations lack Lewy bodies (LBs), a 
neuropathological hallmark of PD. We investigated whether the presence or absence of LBs 
correlates with different clinical features in LRRK2-related PD.
OBSERVATIONS—We describe genetic, clinical, and neuropathological findings of 37 cases of 
LRRK2-related PD including 33 published and 4 unpublished cases through October 2013. Among 
the different mutations, the LRRK2 p.G2019S mutation was most frequently associated with LB 
pathology. Nonmotor features of cognitive impairment/dementia, anxiety, and orthostatic 
hypotension were correlated with the presence of LBs. In contrast, a primarily motor phenotype 
was associated with a lack of LBs.
CONCLUSIONS AND RELEVANCE—To our knowledge, this is the first report of 
clinicopathological correlations in a series of LRRK2-related PD cases. Findings from this selected 
group of patients with PD demonstrated that parkinsonian motor features can occur in the absence 
of LBs. However, LB pathology in LRRK2-related PD may be a marker for a broader parkinsonian 
symptom complex including cognitive impairment.
Mutations in leucine-rich repeat kinase2 (LRRK2)are the most frequent cause of genetic 
Parkinson disease (PD), accounting for at least 4% of autosomal dominant forms of familial 
PD and 1% of sporadic PD worldwide.1 The LRRK2 gene encodes a large multidomain 
protein that includes an enzymatically active central region surrounded by a series of 
putative protein-protein interaction domains.2 Disease-causing mutations are concentrated 
within the central region of the protein, which contains an ROC GTPase domain, a COR 
sequence, and a serine/threonine kinase domain. Thus far, at least 8 
mutations(p.N1437H,p.R1441C/G/H,p.Y1699C,p.G2019S,p.I2020T, and possibly 
p.I1371V) are considered to be pathogenic.p.G2019S is the most frequent mutation but 
penetrance of p.G2019S and other pathogenic LRRK2 mutations is incomplete.3-5
The clinical presentation of manifesting LRRK2 mutation carriers tends to be 
indistinguishable from that of sporadic PD, with mean age at onset of approximately 60 
years and appreciable response to levodopa.6 Conversely, the neuropathological features can 
be a typical for PD and heterogeneous even within kindreds.7 In particular, autopsy studies 
have revealed that Lewy bodies (LBs), which are large intraneuronal protein aggregates 
consisting primarily of α-synuclein,8 are absent in a significant subset of cases. This was a 
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surprising finding because LBs are neuro-pathological hallmarks of PD thought to be central 
to the neurodegenerative process and the clinical expression of PD and other 
synucleinopathies. Here we investigated the correlation of clinical features with LB 
pathology in LRRK2-related PD. This may provide insight into the relationship between α-
synuclein pathology and specific features of the PD symptom complex.9
Methods
All published LRRK2-related autopsy cases up to October 2013 were identified by searching 
for English language articles in PubMed. The search terms LRRK2, Lewy body/bodies, 
pathol ogy/pathological, neuropathology/neuropathological, and/or autopsy/autopsies were 
used. Additional articles were found by searching the reference lists of identified articles and 
the authors’ own files. Authors of published cases and directors of brain banks were 
contacted to identify unpublished cases. Clinical data were extracted from published articles. 
Additional data were obtained by requesting that investigators complete a clinical data form 
(eFigure in the Supplement) if the patient's clinic record was available. Neuropathological 
data were extracted from published articles and/or pathology reports when available. Cases 
were excluded if the associated LRRK2 mutation was not one of the putative pathogenic 
mutations (previously mentioned), the patient did not have a clinical diagnosis of PD, or 
there was minimal or no available clinical and/or pathological information. Epi Info 7 from 
the Centers for Disease Control and Prevention was used for data analysis (www.cdc.gov/
epiinfo/). Categorical variables were compared using the Fisher exact test. Continuous 
variables were compared using the t test. Logistic regression was performed to adjust for 
disease duration and age at death. Adjustment for Alzheimer disease–related pathology was 
made, where indicated, using Braak neurofibrillary tangle stage, which was estimated from 
the available data and dichotomized (≤stage III and ≥ stage IV). When necessary, a 
flattening constant of 1 was added to each cell to allow an odds ratio to be calculated. No 
imputation was made for missing data; patients missing values on an outcome were not 
included in the analysis for that outcome. Because this was an exploratory study, no 
adjustments were made for multiple comparisons. Separate analyses were also performed for 
p.G2019S-only cases. The study was approved by the ethics board of the University Health 
Network, Toronto, Ontario, Canada.
Results
Fifty-nine autopsy cases with LRRK2 variants were identified: 54 published and 5 
unpublished cases. Twenty-two cases were excluded from the analysis: 3 with 
nonpathogenic variants; 2 nonmanifesting LRRK2 mutation carriers without a clinical 
diagnosis of PD; and 17 with insufficient clinical and/or pathological data (eTable 1 in the 
Supplement). No cases were excluded for neurological disease other than PD. Thirty-seven 
LRRK2-related PD cases were included: 33 published and 4 unpublished cases (17 with LBs 
and 20 without LBs) (eTable 2 in the Supplement). Neuronal loss within the substantia nigra 
was reported for all of these cases except for 2, in which these data were not provided. There 
were very limited data on neuronal loss within other brain regions. The demographic and 
genetic features of all included cases are summarized in Table 1. All cases with a p.I2020T 
mutation were of Japanese ethnicity. Cases with or without LBs were similar with respect to 
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sex, disease duration, and age at death. Cases with LBs were more likely to have a 
p.G2019S mutation. The demographic features of p.G2019S cases (11 with LBs and 6 
without LBs) are summarized in Table 2.
Table 3 provides a summary of the frequency of clinical features in LRRK2 cases with or 
without LBs. Tremor was the most common presenting symptom for LRRK2 patients 
regardless of the presence of LBs (65% for both groups). Cardinal motor symptoms, atypical 
features, levodopa responsiveness, and motor complications (see eFigure in the Supplement 
for details) occurred with similar frequency in both groups for all LRRK2 cases and for the 
subset of p.G2019S cases. Certain nonmotor features (documented on history and/or 
examination) were more frequent among LRRK2 cases with LBs. After adjusting for disease 
duration and age at death, cognitive impairment/dementia, anxiety, and orthostatic 
hypotension were associated with the presence of LBs (Table 4). Cognitive impairment/
dementia and anxiety were also associated with the presence of LBs within the subgroup of 
cases with the p.G2019S mutation. The association between cognitive impairment/dementia 
and the presence of LBs was maintained after adjustment for the degree of Alzheimer 
disease–related pathology (odds ratio, 8.14; 95% CI, 1.46-45.47; P = .02 for all LRRK2 
cases and odds ratio, 76.03; 95% CI, 1.07-5414.76; P = .047 for only p.G2019S cases).
Discussion
To our knowledge, this study is the first report of clinicopatho-logical correlations in a series 
of LRRK2-related PD cases. We found that a primarily motor phenotype was associated with 
an absence of LBs. Parkinsonism (ie, bradykinesia plus rigidity, tremor, and/or postural 
instability) occurring independently of LB pathology has also been observed in the context 
of mutations in PARK2, which encodes parkin, where most autopsy reports describe an 
absence of LBs.10 Conversely, LBs have been detected in the brains of people without the 
motor features of PD, an entity termed incidental LB disease. Our findings are consistent 
with these observations that LBs are neither necessary nor sufficient for the clinical 
expression of parkinsonism. Yet, there is strong evidence in experimental mouse models of 
PD that accumulation of α-synuclein aggregates in the substantia nigra pars compacta is 
associated with the death of dopaminergic neurons that harbor these aggregates with 
concomitant loss of tyrosine hydroxylase and dopamine metabolites in the dorsal striatum.11 
There is similar evidence linking α-synuclein aggregates in hippocampus to hippocampal 
neuron loss and cognitive impairment.12 It is proposed that the neuropathological correlate 
of parkinsonian motor features is neuronal loss in the ventrolateral tier of the substantia 
nigra pars compacta.8 However, loss of nigral neurons is also not specific for a diagnosis of 
PD because it occurs in many other neurodegenerative disorders with prominent 
parkinsonism such as progressive supranuclear palsy and multiple system atrophy.
The expression of nonmotor features in this series of LRRK2-related PD cases was found to 
be related to the presence of LBs. In particular, cognitive impairment/dementia, anxiety, and 
orthostatic hypotension were more likely to occur at some point during the disease course in 
patients who were found to have LBs at autopsy. Many nonmotor features tend to occur with 
longer disease duration and/or older age13 but we did not find that these potential 
confounders accounted for the differences observed between those with or without LBs. 
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Evidence for an association between Lewy pathology and nonmotor symptoms has been 
previously demonstrated for cognitive impairment in PD. In particular, several studies have 
demonstrated a strong correlation between dementia and severity of cortical Lewy 
pathology.14-16
Based on our findings, we hypothesize that LRRK2-related PD with LBs is associated with 
more extensive neuro-degeneration whereas neuronal loss may be more restricted (eg, to the 
substantia nigra pars compacta) in cases lacking LBs. This would be similar to parkin-
related PD in which there is frequently an absence of LBs, restricted neurodegeneration, and 
a relative lack of nonmotor features.10 In patients with sporadic PD, cortical Lewy 
pathology correlates with dementia but Alzheimer disease plaques and tangles also 
contribute to their cognitive impairment.16,17 It is possible that aggregates of proteins other 
than α-synuclein are contributors to the clinical expression of LRRK2-related PD. 
Standardized neuropathological assessments of a series of LRRK2 autopsy cases, including 
semiquantitative measures of neuronal loss and examination of various protein aggregates in 
brain stem, subcortical, and cortical structures, are needed to further interrogate correlations 
with specific motor and nonmotor symptoms in LRRK2-related PD.
Prior reports have highlighted the occurrence of atypical neuropathological findings at 
autopsy for some manifesting LRRK2 mutation carriers including pathology resembling 
progressive supranuclear palsy, multiple system atrophy, or frontotemporal lobar 
degeneration with ubiquitin-positive inclusions, presence of TDP-43 inclusions, and/or lack 
of LB pathology (eTable 2). Our assessment was limited to clinical correlations with LBs 
because this was the only neuropatho-logical feature available for all cases. Additional 
details—such as the presence of α-synuclein immunoreactive inclusions in neuronal 
processes (eg, Lewy neurites, dotlike structures, and axonal spheroids), degree of neuronal 
loss, involvement of extranigral structures, immunostaining results for other protein 
inclusions, and the distribution of these features—were unavailable for many cases so 
analysis of these other features could not be carried out here. Furthermore, there is a lack of 
standard operating procedures for the neuropathological diagnosis of PD8 and 
methodological differences (eg, areas sampled, immunostaining performed, and types of 
antibodies used) among the different centers may have produced variable results. Ongoing 
and future efforts to standardize autopsy collection, handling, and reporting for LRRK2-
related PD cases will help to provide data for more detailed clinicopatho-logical 
correlations.
The LRRK2 autopsy cases used in this study were identified primarily from published 
reports; therefore, there is the potential for ascertainment bias. Furthermore, the cases came 
from differing sources (eg, individual cases, large kindreds, and brain banks). The clinical 
data acquired in the study were based on retrospective reports by the patients, caregivers, 
and/or treating physician. The nature of this study precluded standardized clinical 
assessments, which is a significant limitation. An additional limitation includes the potential 
for false-positive findings due to multiple comparisons. Regardless, our observations raise 
the hypothesis that LB pathology may be the underlying basis for cognitive dysfunction in 
LRRK2 disease while at the same time being a marker for a broader parkinsonian symptom 
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complex in LRRK2-related PD. This can be tested in future prospective cohort studies of 
patients with LRRK2 mutations.
An important unresolved question is: why are LBs absent in a subset of patients with 
LRRK2-related PD? The large number of cases reported from various centers demonstrates 
that LB-negative LRRK2-related PD is not an anomalous finding. Genotype cannot account 
for this finding because the subset of patients without LBs is not represented by 1 specific 
LRRK2 mutation. The possibility that LRRK2-related PD represents a distinct disease from 
sporadic PD and thus can present with non-LB pathology is unlikely based on the significant 
clinical similarities between PD associated with LRRK2 mutations and sporadic PD,6 
evidence from genome-wide association studies demonstrating that LRRK2 polymorphisms 
are genetic risk factors for sporadic PD,18 and experimental findings that implicate the 
LRRK2 protein in molecular pathways underlying PD pathogenesis.2 While our study did 
not explain why LBs are sometimes absent in LRRK2-related PD, it contributes to the 
accumulating evidence that LBs alone cannot explain the pathogenesis of PD but other 
forms of α-synuclein may also play important roles.19 Indeed, small soluble aggregates of α-
synuclein have been isolated from the cortex of a patient with G2019S LRRK2 PD without 
LBs.20 Our study also supports the ongoing effort to reevaluate the pathological criteria used 
to define PD, in particular, deemphasizing LBs as a core feature.21
Conclusions
Lewy body pathology is not present in all patients with LRRK2-related PD. The mutation 
p.G2019S is more frequently associated with LB pathology compared with other LRRK2 
mutations. The classic parkinsonian motor symptoms can occur without LBs, and a 
primarily motor phenotype appears to be associated with an absence of LBs. The expression 
of certain nonmotor features, particularly cognitive impairment, anxiety, and orthostatic 
hypotension, is related to the presence of LBs. Thus, LB pathology in LRRK2-related PD 
may be a marker for a broader parkinsonian symptom complex.
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Table 1
Demographic and Genetic Features of all LRRK2 Cases With and Without LB Pathology
Feature With LBs (n = 17) Without LBs (n = 20) P Value
Male, %(no./No.) 23.5 (4/17) 40.0 (8/20) .32
Race/ethnicity
    Non-Asian, % (no./No.) 92.9 (13/14) 57.9 (11/19) .05
        White non-Jewish, No. 10 10
        Ashkenazi Jewish, No. 3 1
    Asian, % (no./No.) 7.1 (1/14) 42.1 (8/19)
Age at onset, mean (SD), y 56.0 (11.2) 61.0 (10.2)a .17
Disease duration, mean (SD), y 19.2 (9.0) 16.2 (6.7) .27
Age at death, mean (SD), y 75.2 (9.3) 77.2 (8.4) .49
LRRK2 mutation
    p.G2019S, % (no./No.) 64.7 (11/17) 30.0 (6/20) .05
    Other, % (no./No.) 35.3 (6/17) 70.0 (14/20)
        p.I2020T, No. 1 8
        p.R1441C, No. 2 2
        p.R1441G, No. 0 2
        p.Y1699C, No. 1 2
        p.N1437H, No. 1 0
        p.I1371V, No. 1 0
Abbreviations: LB, Lewy body; LRRK2, leucine-rich repeat kinase 2.
aSeventeen of 20 cases.
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Table 2
Demographic Features of LRRK2 p.G2019S Cases With and Without LB Pathology
Feature With LBs (n = 11) Without LBs (n = 6) P Value
Male,%(no./No.) 36.4 (4/11) 50.0 (3/6) .64
Race/ethnicity
    Ashkenazi Jewish, % (no./No.) 37.5 (3/8) 20.0 (1/5) >.99
    White non-Jewish, % (no./No.) 62.5 (5/8) 80.0 (4/5)
    Asian, % (no./No.) 0 (0/8) 0 (0/5)
Age at onset, mean (SD), y 57.0 (12.8) 68.0 (7.5) .07
Disease duration, mean (SD), y 21.1 (9.7) 13.5 (4.2) .09
Age at death, mean (SD), y 78.1 (6.6) 81.5 (4.1) .27
Family history of PD, % (no./No.)a 50.0 (5/10) 60.0 (3/5) >.99
Abbreviations: LB, Lewy body; LRRK2, leucine-rich repeat kinase 2.
aAt least 1 first-, second-, and/or third-degree relative with PD.
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Table 3
Frequency of Clinical Features With or Without LB Pathologya
All LRRK2 Cases (N = 37) LRRK2 p.G2019S Cases (n = 17)
Feature With LBs (n = 
17)
Without LBs 
(n = 20)
P Value With LBs (n = 
11)
Without LBs (n=6) P Value
Motor features, % (no./No.)
    Bradykinesia 100 (17/17) 100 (18/18) >.99 100 (11/11) 100 (5/5) >.99
    Rigidity 100 (17/17) 100 (15/15) >.99 100 (11/11) 100 (6/6) >.99
    Tremor 94 (16/17) 94 (16/17) >.99 91 (10/11) 100 (6/6) >.99
    Postural instability 100 (16/16) 92 (12/13) .45 100 (11/11) 80 (4/5) .31
    Atypical features 17 (2/12)b,c 33 (3/9)d .61 11 (1/9)c 0 (0/3) >.99
Nonmotor features, % (no./No.)
    Cognitive impairment/dementia 67 (10/15) 20 (4/20) .01 82 (9/11) 17 (1/6) .03
    Depression 79 (11/14) 38 (3/8) .08 89 (8/9) 67 (2/3) .45
    Anxiety 82 (9/11) 0 (0/7) .002 100 (8/8) 0 (0/3) .006
    Orthostatic hypotension 50 (6/12) 0 (0/13) .005 63 (5/8) 0 (0/3) .18
    Urinary symptoms 40 (4/10) 25 (3/12) .65 57 (4/7) 0 (0/2) .44
    Constipation 78 (7/9) 38 (5/13) .10 100 (6/6) 100 (2/2) >.99
Levodopa treatment, % (no./No.)
    Positive responsee 80 (8/10)f 86 (12/14)g >.99 71 (5/7) 60 (3/5)g >.99
    Fluctuations 67 (10/15) 80 (12/15) .68 64 (7/11) 67 (4/6) >.99
    Dyskinesia 73 (11/15) 62 (8/13) .69 80 (8/10) 50 (3/6) .30
    Maximum levodopa dose, mean 
(SD), mg
798 (431) 836 (504) .85 741 (395) 840 (391) .67
        No. of cases 10 11 8 5
Abbreviations: LB, Lewy body; LRRK2, leucine-rich repeat kinase 2.
a
The results for the features in bold are statistically significant.
bOne patient had supranucleargaze palsy.
cOne patient had upper motor neuron signs and myoclonus.
dOne patient had upper motor neuron signs, 1 patient had supranucleargaze palsy and upper motor neuron signs, and 1 patient had amyotrophy.
e
Percentage of patients with moderate to marked levodopa response.
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fOne patient did not have a trial of levodopa.
gOne patient could not tolerate levodopa.
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Table 4
Clinical Correlates of LB Pathology in LRRK2-Associated Parkinson Diseasea,b
All LRRK2 Cases (N = 37) LRRK2 p.G2019S Cases (n = 17)
Feature OR (95% CI) P Value OR (95% CI) P Value
Motor features
    Bradykinesia 0.95 (0.05-17.97) .97 2.49 (0.08-80.81) .61
    Rigidity 1.22 (0.06-26.80) .90 1.94 (0.07-53.77) .69
    Tremor 1.03 (0.04-26.52) .99 0.60 (0.04-9.19) .71
    Postural instability 2.22 (0.16-30.44) .55 4.55 (0.23-89.65) .32
    Atypical features 0.54 (0.05-6.19) .62 1.38 (0.08-25.39) .83
Nonmotor features
    Cognitive impairment/dementia 9.74 (1.80-52.60) .008 85.64 (1.52-4817.27) .03
    Depression 3.06 (0.36-26.07) .31 3.33 (0.06-184.51) .56
    Anxiety 17.87 (1.37-233.28) .03 24.69 (1.14-536.51) .04
    Orthostatic hypotension 12.03 (1.17-123.93) .04 4.35 (0.31-61.10) .28
    Urinary symptoms 2.25 (0.29-17.46) .44 6.82 (0.36-130.83) .20
    Constipation 14.49 (0.78-267.71) .07 1.95 (0.06-68.51) .71
Levodopa treatment
    Positive response 0.11 (0.01-2.42) .16 0.10 (0-3.21) .19
    Fluctuations 0.10 (0.01-1.53) .10 0.14 (0.01-3.31) .22
    Dyskinesia 0.31 (0.02-4.72) .40 0.92 (0.05-16.14) .95
Abbreviations: LB, Lewy body; LRRK2, leucine-rich repeat kinase 2; OR, odds ratio.
aAdjusted for disease duration and age at death.
b
The results for the features in bold are statistically significant.
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